Cancer therapies that activate only where needed? That’s the promise of conditionally active therapeutics.
Linkedin
March 6, 2026
Podcast
News Archive
For Biotech Entrepreneurs: CDMO Selection is an Overlooked Skill Set
LinkedIn
February 26, 2026
Blog
USPTO Grants Key Mechanism of Action Patent to Bonum Therapeutics for its Conditionally Active Biologics Technology
The patent significantly strengthens Bonum’s intellectual property protecting its Dual-Binding Antibody platform for conditionally regulated therapeutics for a broad range of pairs, including but not limited to LRRC15-IFNa, PD-L1-IFNa, and PD1-IL2
Bonum Therapeutics to Participate in Panel on Conditionally Active Biologics at BIO 2025
Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to its Board of Directors
We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
GeekWire
July 18, 2024
Media
Bonum Therapeutics to double its space in Eastlake after move
Puget Sound Business Journal
July 21, 2024
Media